EP2190417A2 - Compositions pharmaceutiques comprenant un sensibilisateur à l insuline et un secrétagogue d insuline - Google Patents

Compositions pharmaceutiques comprenant un sensibilisateur à l insuline et un secrétagogue d insuline

Info

Publication number
EP2190417A2
EP2190417A2 EP09725377A EP09725377A EP2190417A2 EP 2190417 A2 EP2190417 A2 EP 2190417A2 EP 09725377 A EP09725377 A EP 09725377A EP 09725377 A EP09725377 A EP 09725377A EP 2190417 A2 EP2190417 A2 EP 2190417A2
Authority
EP
European Patent Office
Prior art keywords
solid preparation
insulin
insulin secretagogue
cellulose derivative
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09725377A
Other languages
German (de)
English (en)
Inventor
Itamar Kanari
Minutza Liebovici
Michael Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of EP2190417A2 publication Critical patent/EP2190417A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Definitions

  • compositions comprising Insulin Sensitizer and Insulin Secretagogue
  • Pioglitazone hydrochloride ( ⁇ )-5-[[4-[2-(5-ethyl-2- pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione monohydrochloride is reported to be an oral antihyperglycemic agent that acts primarily by decreasing insulin resistance.
  • Pioglitazone hydrochloride, a member of the thiazolidinedione class is used in the management of type 2 diabetes.
  • Glimepiride l-[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-l- carboxamido)ethyl]phenyl]sulfonyl]-3-(fr ⁇ «5-4-methylcyclohexyl)-urea is an oral blood glucose-lowering drug of the sulfonylurea class and is normally used in the management of type 2 diabetes.
  • Thiazolidinediones are apparently insulin-sensitizing agents that act primarily by enhancing peripheral glucose utilization, whereas sulfonylureas are insulin secretogogues that act primarily by stimulating release of insulin from functioning pancreatic beta cells.
  • Duetact® is available as a tablet for oral administration containing 30 mg pioglitazone hydrochloride (as the base) with 2 mg glimepiride (30 mg/2 mg) or 30 mg pioglitazone hydrochloride (as the base) with 4 mg glimepiride (30 mg/4 mg) formulated with the following excipients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, hydroxypropyl cellulose NF, polysorbate 80 NF, and microcrystalline cellulose NF.
  • US Patent Application Publication No. 2004/0147564 discloses tablets containing glimepiride and a thiazolidinedione, wherein all of the examples have a coating containing polyethylene glycol.
  • a solid preparation comprising an insulin sensitizer and an insulin secretagogue had the undesirable dissolution property of the insulin secretagogue. That is, the dissolution rate of an insulin secretagogue in the solid preparation was slower as compared with that of "a solid preparation containing an insulin secretagogue as a single active ingredient".
  • Doken et al published that the dissolution property of an insulin secretagogue could be improved by incorporating a polyoxyethylene sorbitan fatty acid ester in the solid preparation.
  • the invention provides a solid preparation comprising an insulin sensitizer, an insulin secretagogue, and at least one cellulose derivative, wherein the w/w ratio of cellulose derivative : insulin secretagogue is about 20: 1 to about 100:1, wherein the solid preparation is substantially free of polyoxyethylene sorbitan fatty acid ester, and wherein about 60%, or more, of the insulin secretagogue in the solid preparation dissolves within 45 minutes when measured in 900 mL of an aqueous solution of 0.5% sodium lauryl sulphate and
  • the amount of cellulose derivative may be present in an amount such that the ratio (w/w) of cellulose derivative : insulin secretagogue is at least about 10:1, at least about 15:1, or at least about 30: 1.
  • the solid preparation is substantially free of surfactant and/or substantially free of polyethylene glycol.
  • the insulin sensitizer is pioglitazone and/or the insulin secretagogue is glimepiride.
  • the solid preparation is uncoated.
  • a preferred method for preparing solid preparations of the invention is by wet granulating an insulin sensitizer, an insulin secretagogue, and a cellulose derivative in amounts described herein.
  • substantially free means a functionally insignificant amount. In the case of “substantially free of polyethylene glycol”, this typically means about 0.1%, or less, by weight of the composition. “Substantially free of surfactant” typically means about 0.07%, or less, by weight of the composition. [0016] Although other excipients, such as microcrystalline cellulose, can sometimes function as a filler (as this term is often used in the art), the term “filler” is used herein to refer only to sugars and sugar alcohols.
  • Solid preparations of the invention can be prepared by combining at least one insulin sensitizer, at least one insulin secretagogue, and at least one dissolution enhancer.
  • the solid preparations can be formed by methods known in the art, such as direct compression, wet granulation or dry granulation.
  • Examples of insulin sensitizers include pioglitazone, rosiglitazone, and salts, hydrates and solvates thereof.
  • the insulin sensitizer is pioglitazone hydrochloride or rosiglitazone maleate.
  • insulin secretagogues examples include sulfonylurea agents, such as glimepiride, glipizide, glibenclamide and tolbutamide.
  • the preferred particle size of the active agents is a d(0.5) of less than
  • microns e.g., 1-4 microns.
  • Preferred dissolution enhancers are cellulose derivatives, such as microcrystalline cellulose and low-substituted hydroxypropyl cellulose.
  • cellulose derivatives include microcrystalline cellulose, ethyl cellulose, cellulose acetate, cellulose phthalate, etc.
  • the amount of cellulose derivative is preferably about 20% to about
  • the amount of cellulose derivative is preferably present in an amount such that the ratio (w/w) of cellulose derivative : insulin secretagogue exceeds about 10:1, about 15:1, or equals or exceeds about 30:1.
  • the ratio can be about 20:1 to about 100:1, about 20:1 to about 70: 1, about 30: 1 to about 100: 1, about 30:1 to about 70: 1, about 30:1 to about 60:1, about 30: 1 to about 50: 1, about 40: 1 to about 60: 1 , or about 46: 1 to about 60: 1.
  • other ranges using these ratios or other preferred ratios such as those set forth in the examples, in any combination, may be used.
  • the solid preparations contain a filler, such as lactose and/or one or more polyols, such as mannitol or sorbitol.
  • a filler such as lactose and/or one or more polyols, such as mannitol or sorbitol.
  • the dissolution enhancer : filler w/w ratio is at least 2:1.
  • the dissolution enhancer : filler w/w ratio is about 3: 1 to about 4: 1.
  • the filler or lactose content is about 50%, or less, 0% to about 40%, about 14% to about 20%, about 18% to about 20%, or about 14.5% to about 18% by weight of the composition.
  • Some embodiments of the invention also include excipients commonly found in the art, such as binders, disintegrants, lubricants, colors, flavors, and glidants.
  • Suitable lubricants include, but are not limited to, stearic acid, talc, hydrogenated castor oil, glyceryl behenate, sodium lauryl sulfate, and calcium stearate or combinations thereof.
  • Suitable disintegrants include, but are not limited to, croscarmellose sodium, carboxymethyl cellulose calcium, microcrystalline cellulose, pregelatinized starch, sodium alginate, crospovidone, low-substituted hydroxy propyl cellulose, and colloidal silicon dioxide or combinations thereof.
  • Suitable binders include, but are not limited to, povidone, copovidone, hypromellose, HPC, pregelatinized starch or combinations thereof.
  • the solid preparations are substantially free of surfactants and/or wetting agents, such as sodium lauryl sulphate, Polyoxyethylene Sorbitan Fatty Acid Esters, Sorbitan Fatty Acid Esters, Poloxamers, Carbomers, Acacia gum, Docusate sodium, Polyoxyethylene Alkyl Ethers, Glyceryl monostearate, Polysorbates 20, 40, 60, and 80, and/or Hydrogenated polyoxyl castor oil.
  • surfactants and/or wetting agents such as sodium lauryl sulphate, Polyoxyethylene Sorbitan Fatty Acid Esters, Sorbitan Fatty Acid Esters, Poloxamers, Carbomers, Acacia gum, Docusate sodium, Polyoxyethylene Alkyl Ethers, Glyceryl monostearate, Polysorbates 20, 40, 60, and 80, and/or Hydrogenated polyoxyl castor oil.
  • the solid preparation of the present invention can be further coated using standard coating material, preferably one not comprising polyethylene glycol or surfactants, e.g., SEPIFILM LP 007 or Kollicoat IR.
  • Said coated preparations are preferably substantially free of polyethylene glycol or surfactants.
  • Coating can be achieved, for example, by preparing a coating dispersion then film coating the tablet.
  • the coating can be applied using typical coaters, e.g., horizontal drum coaters, fluidised bed coaters, immersion sword coaters, and coating pans under the usual conditions for aqueous solutions.
  • the solid preparations of the present invention have high stability and industrially acceptable degradation rates.
  • the invention provides a solid preparation comprising an insulin sensitizer, an insulin secretagogue and at least one cellulose derivative, wherein the w/w ratio of cellulose derivative : insulin secretagogue is about 20: 1 to about 100:1, wherein the solid preparation is substantially free of polyoxyethylene sorbitan fatty acid ester, and wherein about 60%, or more, of the insulin secretagogue in the solid preparation dissolves within 45 minutes when measured in 900 mL of an aqueous solution of 0.5% sodium lauryl sulphate and 0.01N HCl using USP paddle apparatus II at 75 rpm at 37 0 C.
  • the invention provides a solid preparation comprising an insulin sensitizer, an insulin secretagogue, and at least one cellulose derivative, wherein at least about 80%, more preferably at least about 85%, of said insulin sensitizer and/or at least about 60%, preferably at least about 65%, of said insulin secretagogue is dissolved within 45 minutes, preferably within 30 minutes, more preferably within 5 minutes, when measured in 900 mL of an aqueous solution of 0.5% sodium lauryl sulphate ("SLS”) and 0.01N HCl using a paddle apparatus (USP Apparatus II) at 75 rpm, 37°C.
  • SLS sodium lauryl sulphate
  • the improvement in dissolution rate achieved by preferred embodiments of the invention may occur by various mechanisms. While not intending to be bound by any particular theory as to how the relatively high concentration of dissolution enhancer, exemplified by microcrystalline cellulose, increases the rate of dissolution of a poorly soluble drug, it was observed in the context of the Examples that solubility was independent of the rate of disintegration.
  • the invention provides a solid preparation comprising between about 30 mg and about 45 pioglitazone hydrochloride, between about 2 mg and about 4 mg glimepiride, and between about 120 and about 180 mg dissolution enhancer.
  • a preferred embodiment contains about 5% to about 23% pioglitazone and/or about 0.3% to about 2% gilperimide and/or about 20% to about 90% dissolution enhancer, w/w of the total composition.
  • the invention provides a solid preparation comprising between about 2 mg and about 8 mg rosiglitazone maleate, between about 1 mg and about 4 mg glimepiride, and between about 120 and about 180 mg dissolution enhancer.
  • Solid preparations of the present invention can be in the form of tablets, capsules, granules, troches, etc.
  • the solid preparation is tablets.
  • An exemplary method for making a solid preparation embodiment by wet granulation includes the steps of: (1) admixing insulin sensitizer, insulin secretagogue, and an intra-granular excipient to form a mixture; (2) preparing a granulation solution; (3) granulating said mixture with said solution to form granules;
  • the mixing time in step (3) is less than about 150 seconds, such as 10-90 seconds or 30-60 seconds, using a Diosna high shear mixer, or an equivalent thereto.
  • the preferred mixing time may vary upon using different mixers.
  • One of ordinary skill in the art can easily determine a preferred mixing time using two criteria. First, the mixture to be mixed to the extent that a good end point is achieved, which one skilled in the art can determine through observation. For example, generally the granulate should not be a dry powder or should not be overly wet and/or clumpy.
  • the preparation resulting from the granulate should be tested for dissolution, hi some cases, for example, overmixing may provide a satisfactory-looking granulate but has a diminished dissolution profile.
  • the granulation solution of step (2) comprises at least one of insulin sensitizer and at least one insulin secretagogue.
  • the intra-granular excipient in step (3) and/or the extra-granular excipient in step (4) may include a dissolution enhancer.
  • the Preparations in Table I comprise pioglitazone hydrochloride as the insulin sensitizer and glimepiride as the insulin secretagogue.
  • Preparations 1-3 contain no dissolution enhancer.
  • the dissolution rate of glimepiride is less than 20% in 15 min and up to 50% in 45 min.
  • Preparation 4 does contain a microcrystalline cellulose, but at a relatively low content, namely about 17% by weight of the total preparation.
  • the cellulose derivative/pioglitazone hydrochloride and cellulose derivative/glimepiride w/w ratios are about 1.1 : 1 and about 17:1, respectively. The dissolution rates do not show a significant improvement.
  • Preparations 5-8 in the table comprise dissolution enhancer at significantly higher contents.
  • the microcrystalline cellulose is about
  • dissolution enhancer/pioglitazone hydrochloride and dissolution enhancer/glimepiride w/w ratios are also high.
  • Preparation 5 part of the dissolution enhancer is incorporated extra- granularly.
  • Preparations 6 and 7 the glimepiride is introduced in the granulation solution.
  • step 2) add the solution from step 2) to the mixture from step 1) in the high shear mixer and mix until a good end point for the wet granulate is obtained;
  • step 4) dry the wet granulate from step 3) in a fluidized bed dryer;
  • step 5) mill the dry granulate from step 4) through a mill (QUADRO COMIL);
  • step 7) add the components of part II to the mixture from step 6) in the Y-cone or Flow-bin and mix;
  • step 10) compress the final blend from step 9) into tablets.
  • Example 4 The formulation of Example 4 was prepared twice according to the method of Example 2, except the mixing time in step (3) was either 45 or 60 seconds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formes galéniques contenant un sensibilisateur à l’insuline, tel que pioglitazone, et un secrétagogue d’insuline, tel que glimépiride. L’inclusion d’un dérivé de cellulose dans la forme galénique augmente la vitesse de dissolution du sensibilisateur d’insuline et/ou du secrétagogue d’insuline.
EP09725377A 2008-03-26 2009-03-26 Compositions pharmaceutiques comprenant un sensibilisateur à l insuline et un secrétagogue d insuline Withdrawn EP2190417A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3969108P 2008-03-26 2008-03-26
PCT/US2009/038365 WO2009120844A2 (fr) 2008-03-26 2009-03-26 Compositions pharmaceutiques comprenant un sensibilisateur à l’insuline et un secrétagogue d’insuline

Publications (1)

Publication Number Publication Date
EP2190417A2 true EP2190417A2 (fr) 2010-06-02

Family

ID=41051025

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09725377A Withdrawn EP2190417A2 (fr) 2008-03-26 2009-03-26 Compositions pharmaceutiques comprenant un sensibilisateur à l insuline et un secrétagogue d insuline

Country Status (2)

Country Link
EP (1) EP2190417A2 (fr)
WO (1) WO2009120844A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101804056A (zh) * 2010-04-16 2010-08-18 山东新华制药股份有限公司 盐酸吡格列酮、格列美脲的复方片剂及制备方法
WO2013034174A1 (fr) 2011-09-06 2013-03-14 ZENTIVA Saglik Ürünleri Sanayi ve Ticaret A.S. Préparations solides de pioglitazone et de glimépiride
CA2987912C (fr) * 2015-06-30 2023-01-24 Genentech, Inc. Comprimes a liberation immediate contenant un medicament et procedes pour former les comprimes
CN112964810A (zh) * 2020-11-26 2021-06-15 石药集团欧意药业有限公司 一种格列美脲片剂在pH1.2溶出介质中的溶出曲线的测定方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
MXPA05007883A (es) * 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
EP1558220B1 (fr) * 2003-07-24 2010-02-10 Wockhardt Limited Compositions orales pour le traitement du diabete
MXPA06004639A (es) * 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009120844A3 *

Also Published As

Publication number Publication date
WO2009120844A2 (fr) 2009-10-01
WO2009120844A3 (fr) 2010-01-28

Similar Documents

Publication Publication Date Title
EP2331074B1 (fr) Granulés, leur procédé de préparation et produits pharmaceutiques les contenant
JP4995798B2 (ja) ナテグリニド含有製剤
TWI428333B (zh) 醫藥組合物
NZ582648A (en) Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof
US20090324718A1 (en) Imatinib compositions
WO2018153925A1 (fr) Compositions pharmaceutiques stables comprenant du macitentan
US20070219250A1 (en) Pharmaceutical Compositions of Nateglinide
US20140051733A1 (en) Febuxostat pharmaceutical compositions
WO2009120844A2 (fr) Compositions pharmaceutiques comprenant un sensibilisateur à l’insuline et un secrétagogue d’insuline
CA2697150A1 (fr) Procedes et compositions pour controler la biodisponibilite de medicaments faiblement solubles
RU2465900C2 (ru) Фармацевтические композиции, содержащие ирбесартан
EP2065035A1 (fr) Formules pharmaceutiques contenant de l'irbesartan
US20180235911A1 (en) Stable pharmaceutical composition of alogliptin and metformin fixed dose combination
WO2022153330A1 (fr) Compositions pharmaceutiques comprenant de l'acalabrutinib
WO2022119543A1 (fr) Procédé de préparation de comprimés comprenant de la dapagliflozine amorphe et du chlorhydrate de metformine
EP4279075B1 (fr) Composition pharmaceutique contenant de l'elagolix
WO2020122244A1 (fr) Comprimé, et procédé de fabrication de celui-ci
WO2013098577A1 (fr) Compositions pharmaceutiques de bosentan
WO2024084496A1 (fr) Compositions pharmaceutiques comprenant du maléate d'acalabrutinib
WO2006013444A1 (fr) Preparations de compositions pharmaceutiques stables de nateglinide et procedes de preparation de celles-ci
WO2023227997A1 (fr) Composition pharmaceutique contenant une combinaison d'azilsartan et de chlorthalidone et son procédé de préparation
EP4321154A1 (fr) Comprimé de tolvaptan et au moins un liant traité par granulation par pulvérisation
WO2022162687A1 (fr) Compositions pharmaceutiques comprenant du nilotinib
EP4212150A1 (fr) Composition de comprimé bicouche comprenant de la dapagliflozine amorphe et de la metformine
KR20160141045A (ko) 보센탄을 함유한 약학적 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091125

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

17Q First examination report despatched

Effective date: 20100708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101119